1. Home
  2. LUCY vs OGEN Comparison

LUCY vs OGEN Comparison

Compare LUCY & OGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Innovative Eyewear Inc.

LUCY

Innovative Eyewear Inc.

N/A

Current Price

$0.69

Market Cap

6.7M

Sector

Health Care

ML Signal

N/A

Logo Oragenics Inc.

OGEN

Oragenics Inc.

HOLD

Current Price

$0.55

Market Cap

2.8M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
LUCY
OGEN
Founded
2017
1996
Country
United States
United States
Employees
N/A
N/A
Industry
Ophthalmic Goods
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
6.7M
2.8M
IPO Year
2021
2010

Fundamental Metrics

Financial Performance
Metric
LUCY
OGEN
Price
$0.69
$0.55
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
163.4K
25.1K
Earning Date
05-14-2026
05-11-2026
Dividend Yield
N/A
N/A
EPS Growth
63.39
N/A
EPS
N/A
N/A
Revenue
$2,661,669.00
N/A
Revenue This Year
$175.92
N/A
Revenue Next Year
$205.56
N/A
P/E Ratio
N/A
N/A
Revenue Growth
62.65
N/A
52 Week Low
$0.65
$0.48
52 Week High
$2.24
$1.45

Technical Indicators

Market Signals
Indicator
LUCY
OGEN
Relative Strength Index (RSI) 43.53 48.77
Support Level $0.66 $0.49
Resistance Level $0.77 $0.59
Average True Range (ATR) 0.04 0.03
MACD 0.00 0.00
Stochastic Oscillator 27.63 55.83

Price Performance

Historical Comparison
LUCY
OGEN

About LUCY Innovative Eyewear Inc.

Innovative Eyewear Inc is engaged in developing and selling eyeglasses and sunglasses, which are designed to allow customers to remain connected to their digital lives, while also offering prescription eyewear and sun protection. Its products include Lucyd Lyte, Nautica, Eddie Bauer, Lucyd Armor line, and Reebok. The firm derive substantially all of its revenue from the sale of smart glasses and custom lenses.

About OGEN Oragenics Inc.

Oragenics Inc is a development-stage biopharmaceutical company dedicated to the research and development of nasal delivery pharmaceutical therapies targeting neurological conditions and infectious diseases. The Company is currently focused on advancing the development and commercialization of its product candidate, ONP-002. ONP-002 is a fully synthetic, non-naturally occurring neurosteroid that is lipophilic and is designed to cross the blood-brain barrier, with the goal of reducing swelling, oxidative stress, and inflammation while restoring proper blood flow through gene amplification. The Company's primary focus is on the development and commercialization of ONP-002 for the treatment of mild traumatic brain injury (mTBI), or concussion.

Share on Social Networks: